دراسة مقارنة بين إيميتيلستات وأفضل علاج متاح لعلاج التليف النقوي (MF) متوسط-2 أو عالي الخطورة لدى المرضى الذين لم يستجيبوا لعلاج مثبطات كيناز جانوس (JAK)
This study is for people in the UK with a rare type of bone marrow cancer called myelofibrosis, specifically those with more serious forms of the condition (intermediate-2 or high-risk) who haven't seen enough improvement from a common type of treatment called a JAK-inhibitor. The main goal is to find out if a new medication, called imetelstat, helps people live longer compared to standard care options. Participants will either receive imetelstat or the best available therapy, and researchers will carefully monitor their health outcomes. This research aims to offer a new treatment option for those whose current treatments are no longer effective.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is looking into a new medication called imetelstat for a rare blood cancer called myelofibrosis. Myelofibrosis affects your bone marrow, where blood cells are made, causing scar tissue to build up. This can lead to various symptoms like tiredness, a swollen tummy from an enlarged spleen, and different blood problems. For some people, a common treatment called a JAK-inhibitor doesn't work well enough or stops working over time. This study is specifically for these individuals, to see if imetelstat could be a better option.
The main aim of this research is to compare imetelstat with other existing treatments to see if it helps people with myelofibrosis live longer. It’s important to find new and effective treatments, especially for those who haven't benefited from previous therapies. By taking part in this study, you would be helping doctors understand if imetelstat can make a real difference in the lives of people living with myelofibrosis.
Participants will be placed into one of two groups: one receiving imetelstat, and the other receiving what doctors consider to be the 'best available therapy' for their condition. Researchers will then carefully track how well these treatments work, focusing on how long people live. This helps gather important information to improve future care for myelofibrosis. Throughout the study, your health will be closely monitored by a medical team.
النقاط الرئيسية
- Tests a new drug (imetelstat) for myelofibrosis.
- For adults who haven't responded to JAK-inhibitor treatments.
- Compares imetelstat to current standard care.
- Aims to see if imetelstat improves how long people live.
- Participation involves screening, treatment, and follow-up.
- يمكنك التوقف عن المشاركة في أي وقت.
من قد يكون مؤهلاً؟
This study is looking for adults aged 18 or older who have been diagnosed with myelofibrosis. This includes people who developed myelofibrosis initially, or after having other blood conditions like essential thrombocythemia or polycythemia vera.
Crucially, you must have a more serious form of myelofibrosis, rated as 'intermediate-2' or 'high-risk'. You also need to have tried a JAK-inhibitor treatment for at least three to six months but haven't seen enough improvement, or your condition has worsened while on it. This means your spleen might not have shrunk enough, your symptoms haven't improved significantly, or your condition has progressed.
It's important that you are not suitable for a stem cell transplant, as this is a different treatment option. The study aims to help those who have run out of other effective treatment options.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Have you been diagnosed with myelofibrosis (primary, post-ET or post-PV)?
- Is your myelofibrosis considered 'intermediate-2' or 'high-risk'?
- Have you previously tried a JAK-inhibitor treatment for at least 3-6 months but it's not working well enough or your condition got worse?
- Are you not currently eligible for an allogeneic stem cell transplant?
ماذا يتضمن المشاركة؟
If you decide to join this study, your journey will happen in a few stages. First, there's a 'screening phase' of up to 28 days. During this time, your medical team will check if you meet all the study requirements. You'll also need to pause any previous treatments, including JAK-inhibitors, for 14 days before starting the study.
Once eligible, you'll be randomly assigned to one of two groups. Two out of three people will receive the new medication, imetelstat, while one out of three will receive the 'best available therapy' – which is the standard treatment your doctor recommends. You'll receive your assigned treatment until it's no longer helping or you decide to stop.
After you stop taking the study treatment, there's a 'follow-up' phase. This means the study team will continue to check in on your health regularly, which could involve appointments, until the study ends, or your situation changes. If you are in the 'best available therapy' group and your condition worsens, there might be an option to switch to imetelstat, if approved by the study sponsor. The total duration of your participation will depend on how you respond to treatment and the overall length of the study.
المخاطر والفوائد المحتملة
Locations (144)
- University of California-San Diego/Moores UCSD Cancer Centerالرمز البريدي المؤكدلا جولا، الولايات المتحدة
- UCLA David Geffen School of Medicineالرمز البريدي المؤكدلوس أنجلوس، الولايات المتحدة
- Smilow Cancer Center at YNHHالرمز البريدي المؤكدنيو هيفن، الولايات المتحدة
- BRCR Medical Center Incالرمز البريدي المؤكدبلانتيشن، الولايات المتحدة
- جامعة جنوب فلوريداالرمز البريدي المؤكدتامبا، الولايات المتحدة
- معهد نورتون للسرطانالرمز البريدي المؤكدلويفيل، الولايات المتحدة
- كلية إيكان للطب في جبل سيناءالرمز البريدي المؤكدنيويورك، الولايات المتحدة
- مركز جامعة ديوك الطبيالرمز البريدي المؤكددرهام، الولايات المتحدة
- Gabrail Cancer Centerالرمز البريدي المؤكدكانتون، الولايات المتحدة
- Prairie Lakes Health Care System, Inc.الرمز البريدي المؤكدWatertown, United States
- The University of Texas MDالرمز البريدي المؤكدهيوستن، الولايات المتحدة
- Northwest Medical Specialties PLLCالرمز البريدي المؤكدسياتل، الولايات المتحدة
أسئلة شائعة
What is myelofibrosis?
Myelofibrosis is a rare type of chronic blood cancer where scar tissue forms in the bone marrow, affecting the production of healthy blood cells.
What is a JAK-inhibitor?
JAK-inhibitors are a type of medicine commonly used for myelofibrosis to help manage symptoms and reduce spleen size. This study is for people who haven't responded well to them.
ماذا يعني "العشوائي"؟
Being 'randomised' means you'll be put into a treatment group by chance, like flipping a coin, to make sure the study results are fair and unbiased. You won't get to choose your group.
What is 'best available therapy'?
This refers to the standard treatments that doctors would typically recommend for your myelofibrosis condition outside of a clinical trial.
هل يمكنني التوقف عن المشاركة في الدراسة إذا أردت؟
Yes, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.